The FDA has released a draft of new guidance addressing common FAQs about the development of potential CGT treatments.
The key benefit of zerlasiran’s approach is its ability to directly target and silence the gene responsible for Lp(a) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback